Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Net Margin (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Net Margin for 6 consecutive years, with 2015.36% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 23975.0% to 2015.36% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1238.52% through Dec 2025, up 200050.0% year-over-year, with the annual reading at 1238.52% for FY2025, 200050.0% up from the prior year.
  • Net Margin hit 2015.36% in Q4 2025 for Insight Molecular Diagnostics, up from 4174.62% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 0.81% in Q1 2023 to a low of 16497.81% in Q4 2022.
  • Historically, Net Margin has averaged 3993.96% across 5 years, with a median of 2015.36% in 2025.
  • Biggest five-year swings in Net Margin: soared 6166383bps in 2021 and later tumbled -1549795bps in 2022.
  • Year by year, Net Margin stood at 999.86% in 2021, then crashed by -1550bps to 16497.81% in 2022, then surged by 91bps to 1558.74% in 2023, then crashed by -45bps to 2255.11% in 2024, then grew by 11bps to 2015.36% in 2025.
  • Business Quant data shows Net Margin for IMDX at 2015.36% in Q4 2025, 4174.62% in Q3 2025, and 1880.69% in Q2 2025.